IBA delivers strong FY 2025 results with solid execution in all segments

Core Insights - IBA reported strong financial results for the fiscal year 2025, achieving record-high revenue and improved profitability, driven by robust commercial momentum in Proton Therapy and a historic order intake [1][2][6] Financial Performance - Total net sales increased by 24% to €620.2 million compared to €498.2 million in FY 2024 [3] - IBA Clinical segment saw a significant growth of 44% in net sales, reaching €395.3 million [3][4] - Gross profit rose to €199.6 million, a 19% increase from €168.1 million in the previous year, although gross margin slightly decreased to 32.2% from 33.7% [3][4] - Adjusted EBITDA surged by 54% to €49.4 million, with an adjusted EBITDA margin of 8.0% [3][4] - Net result increased by 38% to €12.7 million, resulting in earnings per share of €0.43 [3][4] Order Intake and Backlog - Equipment order intake reached a record €452 million, a 41% increase year-over-year, with IBA Clinical contributing significantly with an 81% growth [5] - The backlog hit an all-time high of €1.6 billion, providing strong visibility for future operations [5] Strategic Developments - The acquisition of ORA, a leader in radiochemistry, was completed, enhancing IBA's position in Nuclear Medicine [5][10] - The company successfully closed a €125 million bank refinancing package, strengthening its financial structure [10] Future Outlook - IBA set a Group Adjusted EBIT guidance of at least €32 million for FY 2026, building on the momentum from 2025 [10] - A dividend proposal of €0.25 per share is subject to approval at the Annual General Meeting [10]